SARS-CoV-2 antibodies in the Southern Region of New Zealand, 2020
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.10.20.20215616: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: It was approved by the Health and Disability Ethics Committee (20/NTB/101). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources The primary assay was the Abbott Architect SARS-CoV-2 IgG chemiluminescent microparticle immunoassay (CMIA) (Abbott, Chicago, USA). Abbottsuggested: (Abbott, RRID:SCR_010477)Samples were analysed on the Abbott Architect i2000SR Immunoassay Analyzer following manufacturer’s instructions. Abbott Architectsuggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)Statistical analysis: Statistical analysis was … SciScore for 10.1101/2020.10.20.20215616: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: It was approved by the Health and Disability Ethics Committee (20/NTB/101). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources The primary assay was the Abbott Architect SARS-CoV-2 IgG chemiluminescent microparticle immunoassay (CMIA) (Abbott, Chicago, USA). Abbottsuggested: (Abbott, RRID:SCR_010477)Samples were analysed on the Abbott Architect i2000SR Immunoassay Analyzer following manufacturer’s instructions. Abbott Architectsuggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)Statistical analysis: Statistical analysis was performed using Prism 8 (GraphPad) or R (version 3.6.3) within R Studio (version 1.2.5033); a P-value of ≤0.05 was considered statistically significant. GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has some limitations. Firstly, the delay in specimen collection after the outbreak likely had an impact on the Abbott assay sensitivity. We cannot be certain that undiagnosed cases were not missed using the Abbott assay as our screening test. However, every effort was made to mitigate against this by lowering the cut-off for the initial Abbott screening assay. Lastly, it is important to note that this is not a sero-prevalence study. Participants who self-identified as higher risk were actively recruited, therefore the sero-positivity rate calculated in this group in the SDHB region cannot be extrapolated to the general population.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
